D.E. Shaw & Co
NRIX icon

D.E. Shaw & Co’s Nurix Therapeutics NRIX Stock Holding History

D.E. Shaw & Co’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.48M Sell
184,551
-159,652
-46% -$2.72M ﹤0.01% 2495
2026
Q1 		$5.34M Buy
+344,203
New +$5.71M ﹤0.01% 2123
2025
Q2 		– Sell
-59,923
Closed -$712K – 4600
2025
Q1 		$712K Sell
59,923
-52,918
-47% -$885K ﹤0.01% 3295
2024
Q4 		$2.13M Buy
112,841
+40,001
+55% +$917K ﹤0.01% 2678
2024
Q3 		$1.64M Buy
+72,840
New +$1.65M ﹤0.01% 2873
2023
Q4 		– Sell
-25,358
Closed -$199K – 4503
2023
Q3 		$199K Sell
25,358
-26,144
-51% -$239K ﹤0.01% 3767
2023
Q2 		$515K Sell
51,502
-7,535
-13% -$76.8K ﹤0.01% 3416
2023
Q1 		$524K Sell
59,037
-32,672
-36% -$340K ﹤0.01% 3530
2022
Q4 		$1.01M Buy
91,709
+31,695
+53% +$382K ﹤0.01% 3450
2022
Q3 		$782K Buy
+60,014
New +$950K ﹤0.01% 3765
2021
Q3 		– Sell
-24,012
Closed -$637K – 5137
2021
Q2 		$637K Sell
24,012
-17,186
-42% -$505K ﹤0.01% 3895
2021
Q1 		$1.28M Buy
+41,198
New +$1.56M ﹤0.01% 2910

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co's NRIX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Nurix Therapeutics (NRIX) stake by 46% in Q2 2026, selling an estimated $2.72M and leaving 184,551 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

D.E. Shaw & Co first reported a position in NRIX in Q1 2021 and has held it in 12 quarters since. The position peaked at $5.34M in Q1 2026. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • D.E. Shaw & Co held 184,551 shares of Nurix Therapeutics worth $4.48M as of Q2 2026.
  • D.E. Shaw & Co sold 159,652 Nurix Therapeutics shares in Q2 2026, an estimated $2.72M.
  • Nurix Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2495 holding.
  • D.E. Shaw & Co first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • D.E. Shaw & Co's Nurix Therapeutics position peaked at $5.34M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.